2020 American Transplant Congress
Conversion to a Belatacept Based Immunosuppression Regimen in Renal Transplant Recipients
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Belatacept, a co-stimulation blocker, is an alternative anti-rejection agent that may avoid nephrotoxic or intolerable adverse effects of calcineurin inhibitor (CNI) or mammalian target…2020 American Transplant Congress
Eplet Mismatch Not Correlated with Antibody Mediated Rejection or Allograft Loss Among Kidney Transplant Recipients with De Novo Donor Specific Antibody
1Emory Healthcare, Atlanta, GA, 2Mayo Clinic, Rochester, MN
*Purpose: Eplet mismatches are associated with development of de novo DSA (dnDSA) in kidney transplant recipients. However, it remains unclear how the degree of eplet…2020 American Transplant Congress
Lateral Flow Assay to Detect Soluble CD25 after Kidney Transplantation
Faculty of Natural Sciences, Institute of Technical Chemistry, Hannover, Germany
*Purpose: Kidney transplantations are one of the most common transplantations in the world; 80.696 kidneys were transplanted in 2017. Despite tremendous improvements in quality and…2020 American Transplant Congress
What is the Significance of Denovo Donor Specific Antibodies in Recipients of Simultaneous Liver-Kidney Transplants?
University of Wisconsin, Madison, WI
*Purpose: There is limited information about the utility of donor-specific HLA antibody (DSA) testing and the role of protocol kidney biopsy for de-novo donor-specific antibodies…2020 American Transplant Congress
A Novel Immunoresponse Monitoring System to Predict Chronic Antibody- Mediated Rejection in Kidney Transplant Recipients
1Hokkaido University, Sapporo, Japan, 2Sapporo City General Hospital, Sapporo, Japan
*Purpose: Chronic active antibody mediated rejection (CAAMR) induced by de novo donor specific antibodies (DSA) is the main cause of graft loss in the long-term.…2019 American Transplant Congress
Long Term Outcomes Using Tocilizumab For The Treatment Of Chronic Antibody Mediated Rejection
*Purpose: Limited options exist for the treatment of kidney allograft rejection and preservation of allograft function. We reported our experience with anti-IL-6R (tocilizumab, TCZ) as…2019 American Transplant Congress
Significance of Histopathologic Features for Predicting Progression in Patients with Transplant Glomerulopathy
National Clinical Research Center of Kidney Diseases, Nanjing, China
*Purpose: Transplant glomerulopathy (TG) represents a major cause of long-term allograft failure and is the leading cause of overall post-transplant proteinuria. We aimed to determine…2019 American Transplant Congress
Circulating De Novo Donor Specific Antibodies and Carotid Intima-Media Thickness in Pediatric Kidney Transplant Recipients
*Purpose: Emerging evidence suggests that circulating de novo donor specific anti-HLA antibodies (dnDSA) may be associated with increased risk of accelerated systemic arteriosclerosis and major…2019 American Transplant Congress
CD4 T Cell is Essential in an Innate-Immune Driven Ischemia-Reperfusion Injury in Mouse and Human
*Purpose: Although CD4 T cells are critical in the mechanism of allograft rejection, little is known about their role in the innate immune-driven ischemia-reperfusion injury…2019 American Transplant Congress
MELD Score and Anti-Angiotensin Receptor Antibody Predict Long-Term Survival of Liver Re-Transplant
*Purpose: Recent reports indicated important while inconsistent roles of preformed donor specific antibody (DSA) to HLA in liver transplantation. Re-transplant liver patients were understudied due…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 57
- Next Page »